ARQT · Arcutis Biotherapeutics, Inc. · Insider Trading

The transactions reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on June 5, 2026, by the Reporting Person, with a plan end date of September 1, 2027.

The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.01, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

The option is fully vested.

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

The option is fully vested.

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

The option is fully vested.

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

The transactions reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on June 5, 2026, by the Reporting Person, with a plan end date of September 1, 2027.

The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.12, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service.

The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.

The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.

The option is fully vested.

The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service.

The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service.

The option is fully vested.

The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.

The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.

The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.

The option is fully vested.

The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.

The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.2228, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

The option is fully vested.

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

The option is fully vested.

The option is fully vested.

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.10 to $26.25 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.00 to $26.19, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $26.50 to $26.57, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Includes 823 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2026.

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Includes 712 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2026.

The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of June 5, 2027, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date.

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

The option is fully vested.

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

The option is fully vested.

1/3 each of the underlying shares subject to the option vest and become exercisable on the first annual anniversary of July 15, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the non-employee director's continued service through each applicable vesting date.

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director of the Company. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of June 5, 2027, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date.

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

The option is fully vested.

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

The option is fully vested.

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.095 to $24.62, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.

The option is fully vested.

The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 13, 2026, by the Reporting Person, with a plan end date of June 15, 2027.